STAT
OCTOBER 29, 2024
Vaccines are the original immunotherapy, in the view of Ryan Sullivan, a cancer immunotherapy researcher and oncologist at Mass General Cancer Center. But many other modes of immunotherapy for cancer were approved first — checkpoint blockade drugs like Keytruda and engineered immune cell therapies like Yescarta.
STAT
MAY 7, 2024
Drug development is essentially a long, expensive bet: 90% of drugs fail during clinical trials, goes one of the life science industry’s most oft-quoted statistics. But they cautioned that the pace of future successes will depend on whether the industry can streamline and rethink drug development.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
MARCH 22, 2024
Drug development is more of a sprint than a marathon these days, thanks to more and better ways to target underlying biology and a more nuanced interpretation of precision medicine, three biotech leaders said at the STAT Breakthrough Summit East in New York Thursday. Continue to STAT+ to read the full story…
STAT
APRIL 10, 2024
SAN DIEGO — Cancer vaccines have traveled a potholed road over the last decade. The promise has long been an affordable, personalized cancer vaccine that could train the immune system to recognize proteins from cancer cells and, subsequently, destroy the tumor.
STAT
DECEMBER 6, 2023
A study billed as the last chance to develop an HIV vaccine this decade has been shut down, investigators announced Wednesday at a conference in Harare, Zimbabwe. The trial, known as PrEPVacc, was testing two different vaccine regimens on about 1,500 volunteers in East and Southern Africa. Read the rest…
STAT
JUNE 17, 2024
Today, we talk about the uptick in physicians using ctDNA to determine if resected cancers are truly gone, we see the FDA offering new guidelines for Covid-19 vaccines, and more. Sign up to get our biotech newsletter in your inbox. Read the rest…
STAT
FEBRUARY 9, 2024
Also, Moderna’s RSV vaccine efficacy seems lackluster compared to competitors, and the Bernie Sanders drug pricing song-and-dance did not seem to faze pharma CEOs. Sign up to get our biotech newsletter in your inbox. Give it a listen. Read the rest…
Expert insights. Personalized for you.
351 
Let's personalize your content